London a British drugmaker GlaxoSmithKline saw third quarter net income rise to $824 million from $614 million a year earlier as it benefits from a recent asset swap with rival Novartis. The company said Wednesday that sales of consumer healthcare products rose 55 percent with the start of over-the-counter sales of Flonase in the U.S. and a strong performance from pain relievers Voltaren and Panadol in Europe.